Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 9 recruiting now full pipeline

Burns: full-pipeline trial registry

9 of 37 indexed Burns trials are currently recruiting.

Corpus placement: #406 of 28,707 conditions by registered trial count.

37 US clinical trials · 9 currently recruiting · #406 of 28,707 conditions by registered trial count

Burns: 37 US clinical trials tracked, 9 recruiting.

Burns is the subject of 37 registered US clinical trials on ClinicalTrials.gov, 9 of them currently open to new participants. 9 are in Phase 3-4 (later-stage) and 9 in Phase 1-2 (earlier-stage). The most active sponsor is Massachusetts General Hospital, running 5 of these trials.

Enrollment posture brief

Registry condition burns

OPEN 9 | RECR 24% | LATE 9 | EARLY 9 | RANK #406 | SPON 5

Nearest open-share peer: Anatomic Stage IIB Breast Cancer AJCC v8 (24% recruiting · 33 trials)

Biliary Tract Cancer64.9%Breastfeeding45.9%Graft Vs Host Disease32.4%Chronic Obstructive Pulmonar29.7%Burns (this)24%
Open-enrollment share among volume-matched conditions near Burns

Burns lists 9 open slots (24% of 37 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Burns on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Burns is recruiting below its size-band peers.

    9 of 37 indexed trials (24.3%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. Sponsorship of Burns trials is spread across many organizations.

    Massachusetts General Hospital accounts for 5 of 37 trials (13.5%). 24 distinct sponsors appear on at least one study for this condition label.

  3. Most Burns trials plan to enrol fewer than 100 people.

    Median target enrolment is 26 among the 37 trials that report a genuine target (sentinel values excluded). 28 of those (75.7%) plan for fewer than 100 participants.

  4. Burns research is mostly interventional.

    30 interventional and 7 observational studies make up this index (81.1% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 14Phase 25Phase 34Phase 45

Open and recent trials

37 total, page 1 of 1

RECRUITING 400 participants

Understanding the Burn Wound Microbiome: Comparing Traditional Wound Cultures to Next Generation Sequencing Technology

The University of Texas Medical Branch, Galveston

NCT05275335

RECRUITING Phase 2 200 participants

4-Aminopyridine to Treat Skin Burns

John Elfar

NCT06596434

RECRUITING Phase 4 75 participants

Liposomal Bupivacaine Versus Lidocaine for Skin Graft Donor Site Pain

University of Kansas Medical Center

NCT03854344

RECRUITING Phase 4 62 participants

Burn Study- Tranexamic Acid Versus Thrombin in Split Thickness Skin Graft

University of Kansas Medical Center

NCT06379724

RECRUITING Phase 2 60 participants

Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns

Skingenix

NCT01297400

RECRUITING NA 30 participants

Impact of a Telerehabilitation Program With Technology Enhancement on Post-burn Recovery

The University of Texas Medical Branch, Galveston

NCT06162052

RECRUITING Phase 4 24 participants

Pilot Study: KeraStat® Gel for Topical Delivery of Morphine for Management of Non-Healing, Painful Open Wounds and Ulcers

The Metis Foundation

NCT05217160

RECRUITING NA 21 participants

Suprathel® Use During Prolonged Field Care to Promote Healing and Reduce the Need for Grafting of Burn Wounds

The Metis Foundation

NCT05462860

RECRUITING Phase 4 20 participants

Microsurfaced Grafts in Deep Burn Wounds

CellTherX

NCT04589442

ACTIVE NOT RECRUITING NA 150 participants

Assessment of Safety and Effectiveness of NovoSorb® BTM in Severe Burns

PolyNovo Biomaterials Pty

NCT04090424

ACTIVE NOT RECRUITING NA 66 participants

Conditioning & Open-Label Placebo (COLP) for Opioid Management in Intensive Inpatient Rehabilitation

Spaulding Rehabilitation Hospital

NCT05351333

COMPLETED 610 participants

Inflammation and the Host Response to Injury (Trauma)

Massachusetts General Hospital

NCT00257231

COMPLETED 280 participants

Inflammation and the Host Response to Injury (Burns)

Massachusetts General Hospital

NCT00257244

COMPLETED 251 participants

DeepView SnapShot Portable (DV-SSP): Device Training Study

SpectralMD

NCT05023135

COMPLETED Phase 2 169 participants

Phase 2 Trial of TD 6424 (Telavancin) Versus Standard Therapy for Complicated Gram Positive Skin and Skin Structure Infections (Gram Positive cSSSI)

Cumberland Pharmaceuticals

NCT00061633

COMPLETED NA 101 participants

A Multicenter Comparative Study of the ReCell Device and Autologous Split-thickness Meshed Skin Graft in the Treatment of Acute Burn Injuries

Avita Medical

NCT01138917

COMPLETED 100 participants

SSD vs Collagenase in Pediatric Burn Patients

Children's Mercy Hospital Kansas City

NCT00787592

COMPLETED 60 participants

Effect of Burn Size on Cytomegalovirus Reactivation and Correlates of T Cell Immune Function in Burned Patients

University of North Carolina, Chapel Hill

NCT00467532

COMPLETED Phase 2 36 participants

VR for Burn Dressing Changes at Home

Nationwide Children's Hospital

NCT04548635

COMPLETED Phase 1 30 participants

StrataGraft® Skin Tissue as an Alternative to Autografting Deep Partial-Thickness Burns

Stratatech, a Mallinckrodt Company

NCT01437852

COMPLETED Phase 3 27 participants

Open Multi-centre Investigation to Evaluate Signs and Symptoms of Local Inflammation/Infection on Chronic Ulcers and Partial Thickness Burns When Using Mepilex Border Ag as an Anti-microbial Wound Dressing

Molnlycke Health Care AB

NCT01214811

COMPLETED NA 26 participants

Virtual Reality in Burn Pain Management

United States Army Institute of Surgical Research

NCT00593086

COMPLETED NA 23 participants

Vashe Wound Therapy Study

Valleywise Health

NCT00586729

COMPLETED Phase 1 20 participants

Patient-Controlled Anxiolysis With Dexmedetomidine (PCA-DEX) for Burn-care Dressing Changes

Ohio State University

NCT02409810

COMPLETED Phase 2 20 participants

Cranial Electrotherapy Stimulation in Burned Patients

United States Army Institute of Surgical Research

NCT00723008

COMPLETED Phase 3 20 participants

Effect of rFVIIa on Peri-operative Blood Loss in Patients Undergoing Major Burn

United States Army Institute of Surgical Research

NCT00243243

COMPLETED NA 19 participants

Ultrasound-Guided Block of the Lateral Femoral Cutaneous Nerve in Pediatric Patients

Massachusetts General Hospital

NCT01500655

COMPLETED NA 17 participants

Randomized Control Trial of CO2 Laser to Treat Hypertrophic Burn Scar

Massachusetts General Hospital

NCT03692273

COMPLETED NA 15 participants

Assessment of Safety and Effectiveness of Biodegradable Temporizing Matrix in the Treatment of Deep Burn Skin Injuries

PolyNovo Biomaterials Pty

NCT02905435

COMPLETED 15 participants

Burn Outcomes in Young Adult Burn Survivors

Massachusetts General Hospital

NCT01254357

COMPLETED NA 14 participants

VR for Pain Management During Adult Burn Dressing Change

Nationwide Children's Hospital

NCT04545229

COMPLETED NA 10 participants

Virtual Reality Hypnosis for Chronic Pain Reduction

University of Washington

NCT01099657

COMPLETED Phase 4 10 participants

Comparison of Wound Bed Establishment in Facial Burns

University of Louisville

NCT01668030

COMPLETED Phase 3 7 participants

Comparison of Reversal of Neuromuscular Blockade With Sugammadex Versus Neostigmine Plus Glycopyrolate in Patients Undergoing Burn Surgery

University of Kansas Medical Center

NCT03513406

COMPLETED Early Phase 1 7 participants

Amnion Wound Covering for Enhanced Wound Healing

Wake Forest University Health Sciences

NCT03754218

COMPLETED Phase 1 1 participants

Safety of Extracellular Vesicles for Burn Wounds

Aegle Therapeutics

NCT05078385

COMPLETED Phase 3 1 participants

StrataGraft Safety, Tolerability and Efficacy in Pediatric Subjects

Stratatech, a Mallinckrodt Company

NCT05517902

Phase Distribution

PhaseTrial count
Phase 1 4
Phase 2 5
Phase 3 4
Phase 4 5

Named interventions

Most-linked intervention names on Burns records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Vancomycin or antistaphylococcal penicillin Drug
1 trials
SOC Wound Covering Procedure
1 trials
Amnion Membrane Powder Drug
1 trials
VR-PAT Device
1 trials
Questionnaire self report Other
1 trials
StrataGraft Biological
1 trials
Bacitracin Drug
1 trials
Enzymatic agent Drug
1 trials

US sites by state

Facility locations filed on Burns trials. A trial with sites in several states counts in each.

Texas 11 trials
North Carolina 9 trials
Arizona 8 trials
Massachusetts 6 trials
California 6 trials
Ohio 4 trials
Kansas 4 trials
Florida 4 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Burns page

37 registered trials, 9 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Burns condition card totals 37 registered trials; most-linked intervention Vancomycin or antistaphylococcal penicillin; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.